drug_type
RELEVANT_DRUG
intervention_type
Antibody–drug conjugate (ADC)
drug_description
Anti‑HER2 antibody–drug conjugate (RC48) that delivers the microtubule inhibitor MMAE via a cleavable linker; binds HER2 on urothelial tumor cells, is internalized, releases MMAE to disrupt microtubules (G2/M arrest → apoptosis), with potential bystander effect and Fc‑mediated ADCC.
nci_thesaurus_concept_id
C169918
nci_thesaurus_preferred_term
Disitamab Vedotin
nci_thesaurus_definition
An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds to HER2 on the surface of tumor cells. Following internalization, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
drug_mesh_term
disitamab vedotin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-HER2 antibody–drug conjugate (RC48). The anti-HER2 IgG binds HER2 on tumor cells, is internalized, and a cleavable linker releases MMAE, which inhibits tubulin polymerization to induce G2/M arrest and apoptosis; may also mediate bystander killing and Fc-dependent ADCC.
drug_name
Disitamab vedotin
nct_id_drug_ref
NCT06187506